Quick Answer
Evofem Biosciences, Inc. reported Total Revenue of $19.36 million for fiscal year 2024.
Evofem Biosciences, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2024 | $19.36M | +6.3% |
| 2023 | $18.22M | +8.2% |
| 2022 | $16.84M | +104.2% |
| 2021 | $8.24M | +1748.4% |
| 2020 | $446.0K | — |
| 2019 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.95M | +10.1% | +2.6% |
| June 30, 2025 | $4.83M | +16.0% | +471.0% |
| March 31, 2025 | $845.0K | -76.5% | -81.2% |
| September 30, 2024 | $4.50M | -12.1% | +8.1% |
| June 30, 2024 | $4.16M | +69.2% | +15.5% |
| March 31, 2024 | $3.60M | -38.0% | -29.5% |
| September 30, 2023 | $5.11M | -19.8% | +108.0% |
| June 30, 2023 | $2.46M | -59.3% | -57.7% |
- Evofem Biosciences, Inc. showed an increase of +6.3% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Evofem Biosciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: